CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Candel Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$8.21+0.02 (+0.24%)

Close on Oct 19, 2026

Market cap: $608.62M
P/E (TTM): –
Dividend yield: –

Candel Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	120	103	36	70	83	35	5.45
Cash & Short-Term Investments	120	103	36	70	83	35	5.45
Prepaid Expenses & Other	1.66	1.15	1.38	1.89	2.30	0.09	–
Total Current Assets	121	104	37	72	85	35	–
Property, Plant & Equipment	1.64	2.19	3.21	4.42	3.84	2.79	–
Gross Property, Plant & Equipment	5.20	5.27	5.30	5.55	4.19	2.92	–
Accumulated Depreciation	-3.56	-3.08	-2.09	-1.13	-0.35	-0.13	–
Operating Lease Right-of-Use Assets	1.66	0.54	0.82	1.06	–	–	–
Other Long-Term Assets	–	–	–	–	0.42	0.35	–
Total Assets	125	107	41	78	89	38	–
Accounts Payable	1.13	0.24	0.42	0.38	1.59	0.92	–
Accrued Expenses	7.33	5.11	4.36	4.72	3.44	3.14	–
Current Portion of Long-Term Debt	0	9.90	8.89	–	–	–	–
Current Debt	0	9.90	8.89	–	–	–	–
Current Portion of Leases	0.45	0.57	0.51	0.46	–	–	–
Other Current Liabilities	0.09	0	–	0.05	0.33	0.19	–
Total Current Liabilities	9.00	38	14	5.62	5.36	4.71	–
Long-Term Debt	–	1.73	12	–	–	–	–
Long-Term Leases	1.46	0.41	0.97	1.49	–	–	–
Operating Lease Liabilities	1.90	0.97	1.49	1.95	–	–	–
Total Liabilities	73	41	28	30	25	13	–
Total Debt	0	12	21	–	–	–	–
Common Stock	0.55	0.47	0.29	0.29	0.29	0.12	–
Additional Paid-In Capital	282	259	150	147	144	20	–
Retained Earnings	-230	-192	-137	-99	-80	-44	–
Treasury Stock	-0.45	-0.45	-0.45	-0.45	–	–	–
Shareholders' Equity	52	66	13	48	64	-24	-8.04
Total Equity	52	66	13	48	64	-24	-8.04
Total Liabilities & Equity	125	107	41	78	89	38	–
Shares Outstanding(shares)	55	47	29	29	29	12	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -64.6%

Financial strength

Current ratio: 16.09
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1589.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.83
Dividend yield: –